Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF ACCRUED EXPENSES (Details)

v3.24.1.u1
SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Accrued pre-clinical and clinical costs $ 700,430 $ 1,449,188
Accrued product development costs 1,506,800 745,447
Accrued license costs 4,525,000 4,825,000
Accrued compensation 800,246 2,325,488
Accrued administrative costs 420,008 343,285
Accrued interest 1,445,741 1,342,098
Total $ 9,398,225 $ 11,030,506